News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

News|Articles|May 3, 2024

What Everyone Is Excited About at the 2024 APA Annual Meeting

Author(s)Psychiatric Times Editors

We asked some of the presenters and attendees of the upcoming 2024 APA Annual Meeting what they were excited about. Here's what they said.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

schizophrenia

Real-World and Long-Term Trial Data Show Xanomeline/Trospium Cuts Hospitalizations, Antipsychotic Burden in Schizophrenia

ByPsychiatric Times Editors

July 30th 2026

visoot/Adobe Stock

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

ByJessica Walters

July 30th 2026

Laflor2000/peopleimages.com/Adobe Stock

Making Sense of the New Alzheimer Treatment Landscape, With Aaron Ritter, MD

ByJessica Walters,Aaron Ritter, MD

July 30th 2026

Defining and Treating Agitation in Alzheimer Disease, With Jason Kellogg, MD

Defining and Treating Agitation in Alzheimer Disease, With Jason Kellogg, MD

ByJason Kellogg, MD

July 28th 2026

Neuroplasticity, Novel Targets, and the Future of Depression Pharmacotherapy

Neuroplasticity, Novel Targets, and the Future of Depression Pharmacotherapy

ByJason Kellogg, MD

July 27th 2026

Latest CME

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Expert Illustrations & Commentary: Visualizing the Role of Novel Muscarinic Agents in the Management of Schizophrenia

Ilan Melnick, MD; Linda Collado, MD, DABPN, FAPA; Maria Collado, MD, FAPA

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Patricia Junquera, MD; Maria Collado, MD; Erin C. Crown, MHSPAS, PA-C, Psych-CAQ

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Expert Illustrations & Commentary: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Juan D. Oms, MD, FAPA; Linda Collado, MD, DABPN, FAPA; Ginger Shupe, MD

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CPE Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

PET Imaging Confirms Lower Muscarinic M1 Receptor Availability in Schizophrenia

Making Sense of the New Alzheimer Treatment Landscape, With Aaron Ritter, MD

What's New in Psychiatric Treatment? Highlights From the 2026 Southern California Psychiatry Conference

Real-World and Long-Term Trial Data Show Xanomeline/Trospium Cuts Hospitalizations, Antipsychotic Burden in Schizophrenia

The Weight of Performance: Athletic Identity and Eating Disorders in Male Athletes